Package Leaflet: Information for the Patient
Doprilten 18 mg prolonged-release tablets EFG
Doprilten 27 mg prolonged-release tablets EFG
Doprilten 36 mg prolonged-release tablets EFG
Doprilten 54 mg prolonged-release tablets EFG
methylphenidate hydrochloride
Read the entire package leaflet carefully before you start taking this medicine, as it contains important information for you.
Contents of the package leaflet
What it is used for
Doprilten is used to treat "Attention Deficit Hyperactivity Disorder" (ADHD).
Doprilten is not indicated for the treatment of ADHD in children under 6 years of age.
How it works
Doprilten improves the activity of certain parts of the brain that are underactive. The medication may help improve attention (level of attention), concentration, and reduce impulsive behavior.
The medication is given as part of a comprehensive treatment program, which usually includes:
It is only prescribed by doctors who have experience in behavioral problems in children, adolescents, or adults. If you are an adult and have not received treatment before, the specialist will perform tests to confirm that you have had ADHD since childhood. Although ADHD has no cure, it can be controlled using comprehensive treatment programs.
About ADHD
Children and adolescents with ADHD have difficulty:
It is not their fault that they cannot do these things.
Many children and adolescents struggle to do these things. However, ADHD can cause problems in daily life. Children and adolescents with ADHD may have difficulty learning and doing homework. They have difficulty behaving well at home, at school, and in other places.
Adults with ADHD often have difficulty concentrating. They often feel restless, impatient, and distracted. They may have difficulty organizing their private life and work.
Not all patients with ADHD need treatment with medication.
ADHD does not affect intelligence.
Do not take Doprilten if you or your child:
Do not take methylphenidate if you or your child have any of the above. If you are not sure, tell your doctor or pharmacist before you or your child take methylphenidate. This is because methylphenidate can make these problems worse.
Warnings and precautions
Tell your doctor before you or your child start taking Doprilten if you or your child:
Other mental health problems include:
Tell your doctor or pharmacist if you or your child have any of the above before starting treatment. This is because methylphenidate can make these problems worse. Your doctor will want to monitor how the medication affects you or your child.
During treatment, male patients may experience unexpected prolonged erections. The erections can be painful and occur at any time. It is essential to contact your doctor immediately if the erection lasts more than 2 hours, especially if it is painful.
Checks that your doctor will make before you or your child start taking Doprilten
To decide if methylphenidate is the right medicine for you or your child, your doctor will talk to you about:
Your doctor will explain specifically if you or your child are at risk of mood changes (from being manic to being depressed, known as bipolar disorder). He will check your or your child's mental health history and check if any family members have a history of suicide, bipolar disorder, or depression.
It is essential to provide all the information you can. This will help your doctor decide if methylphenidate is the right medicine for you or your child. Your doctor may decide that you or your child need other medical tests before starting to take this medicine. For adults who start taking Doprilten, your doctor may refer you to a cardiologist.
Other medicines and Doprilten
Tell your doctor if you or your child are taking, have recently taken, or might take any other medicines.
Do not take methylphenidate if you or your child:
Tell your doctor or pharmacist if you or your child are taking any of the following medicines for depression or anxiety:
Taking methylphenidate with these types of medicines can cause a potentially life-threatening increase in "serotonin" in the brain (serotonin syndrome), which can cause confusion or restlessness, sweating, shivering, muscle spasms, or rapid heartbeat. If you or your child experience these side effects, see a doctor immediately.
If you or your child are taking other medicines, methylphenidate can affect how they work or cause side effects. If you or your child are taking any of the following medicines, talk to your doctor or pharmacist before taking methylphenidate:
If you are unsure if any of the medicines you or your child are taking are included in the list above, talk to your doctor or pharmacist for advice before taking methylphenidate.
Before an operation
Tell your doctor if you or your child are going to have an operation. You should not take methylphenidate on the day of the operation with certain types of anesthetics, as it can cause a sudden increase in blood pressure during the procedure.
Drug tests
This medicine can give a positive result in drug tests, even in tests used in sports.
Doprilten with alcohol
Do not drink alcohol while taking this medicine. Alcohol can make the side effects of this medicine worse. Remember that some foods and medicines contain alcohol.
Pregnancy, breastfeeding, and contraception
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, talk to your doctor before using this medicine.
The available data do not suggest an increased risk of total congenital anomalies, although a small increase in the risk of cardiac malformations during use in the first three months of pregnancy could not be ruled out. Your doctor will give you more information about this risk.
Talk to your doctor or pharmacist before using methylphenidate if you or your daughter:
Driving and using machines
You or your child may feel dizzy, have problems focusing, or have blurred vision when taking methylphenidate. If this happens, it can be dangerous to do certain activities such as driving, operating machinery, riding a bike or horse, or climbing trees.
This medicine can affect your ability to drive.
Doprilten contains lactose
If your doctor has told you that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
How much to take
Follow your doctor's instructions for taking this medicine exactly. If you are unsure, talk to your doctor or pharmacist again.
The tablet should be swallowed whole and not chewed, broken, or crushed. The tablet can be taken with or without food.
Use in children from 6 years of age
The recommended initial dose of Doprilten is 18 mg once a day for children who are not currently taking methylphenidate or for children who are switching from another stimulant to methylphenidate.
The maximum daily dose is 54 mg.
Use in adults
If you or your child do not feel better after 1 month of treatment
Tell your doctor. Your doctor may decide that you or your child need a different treatment.
What your doctor will do when you or your child are on treatment
Your doctor will perform some tests
Long-term treatment
Doprilten does not need to be taken indefinitely. If you or your child take Doprilten for more than a year, your doctor should interrupt treatment for a short period, which may be during school holidays. This allows your doctor to check if the medicine is still needed.
Incorrect use of Doprilten
If Doprilten is not used correctly, it can cause abnormal behavior. This can also mean that you or your child start to depend on the medicine. Tell your doctor if you or your child have abused or been dependent on alcohol, prescription drugs, or drugs.
This medicine is only for you or your child. Do not give this medicine to anyone else, even if they have similar symptoms.
If you or your child take more Doprilten than you should
If you or your child take too many tablets, talk to your doctor or go to the emergency department of your nearest hospital immediately and tell them how many tablets you have taken. You may need medical treatment.
Signs of overdose may include: being sick, agitation, tremors, increased uncontrolled movements, muscle contractions, seizures (which can be followed by coma), feeling very happy, confusion, seeing, hearing, or feeling things that are not real (hallucinations), sweating, flushing, headache, high fever, changes in heartbeat (slow, fast, or irregular), high blood pressure, dilated pupils, dry nose and mouth, muscle inflammation, weakness, sensitivity, and muscle pain, and dark urine.
In case of overdose or accidental ingestion, contact the Toxicology Information Service. Phone 91 562 04 20, indicating the medicine and the amount taken. It is recommended to take the packaging and the package leaflet of the medicine to the healthcare professional.
If you or your child forget to take Doprilten
Do not take a double dose to make up for forgotten doses. If you or your child forget a dose, wait and take the next dose at the scheduled time.
If you or your child stop taking Doprilten
If you or your child stop taking this medicine suddenly, ADHD symptoms may come back or unwanted effects such as depression may occur. Your doctor may want to gradually reduce the amount of medicine you take each day before stopping it completely. Talk to your doctor before stopping treatment with Doprilten.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. Although some people present adverse effects, most people are helped by methylphenidate. Your doctor will inform you about these adverse effects.
Some adverse effects can be serious. If you or your child have any of the following adverse effects, go to your doctor immediately:
Frequent (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very Rare (may affect up to 1 in 10,000 people)
Frequency Not Known (frequency cannot be estimated from available data)
If you or your child have any of the above adverse effects, go to your doctor immediately.
Other adverse effects are indicated below, and if they become severe, please inform your doctor or pharmacist:
Very Common (may affect more than 1 in 10 people)
Frequent (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very Rare (may affect up to 1 in 10,000 people)
Frequency Not Known (frequency cannot be estimated from available data)
Effects on Growth
When used for more than a year, methylphenidate may reduce growth in some children. This affects less than 1 in 10 children.
Reporting of Adverse Effects:
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date shown on the packaging. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Validity period after first opening the bottle:
18 mg prolonged-release tablets: 3 months
27, 36, 54 mg prolonged-release tablets: 6 months
Medicines should not be thrown away in drains or trash. Deposit the packaging and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Doprilten
The active ingredient is methylphenidate hydrochloride
Doprilten 18 mg prolonged-release tablets: each prolonged-release tablet contains 18 mg of methylphenidate hydrochloride, equivalent to 15.6 mg of methylphenidate.
Doprilten 27 mg prolonged-release tablets: each prolonged-release tablet contains 27 mg of methylphenidate hydrochloride, equivalent to 23.3 mg of methylphenidate.
Doprilten 36 mg prolonged-release tablets: each prolonged-release tablet contains 36 mg of methylphenidate hydrochloride, equivalent to 31.1 mg of methylphenidate.
Doprilten 54 mg prolonged-release tablets: each prolonged-release tablet contains 54 mg of methylphenidate hydrochloride, equivalent to 46.7 mg of methylphenidate.
Other components are:
Core of the tablet
Lactose monohydrate, hypromellose, anhydrous colloidal silica, magnesium stearate, fumaric acid, methacrylic acid copolymer, and methacrylate (1:1), methacrylic acid copolymer, and methacrylate (1:2), triethyl citrate, talc.
Tablet coating
18 mg prolonged-release tablets:partially hydrolyzed polyvinyl alcohol, macrogol (3350), talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
27 mg prolonged-release tablets:partially hydrolyzed polyvinyl alcohol, macrogol (3350), talc, titanium dioxide (E171), yellow iron oxide (E172), carmine aluminum lacquer (E132), black iron oxide (E172)
36 mg prolonged-release tablets:partially hydrolyzed polyvinyl alcohol, macrogol (3350), talc, titanium dioxide (E171)
54 mg prolonged-release tablets:partially hydrolyzed polyvinyl alcohol, macrogol (3350), talc, titanium dioxide (E171), red iron oxide (E172)
Printing ink
Lacquer, black iron oxide (E172), propylene glycol.
Appearance of the Product and Package Contents
Doprilten 18 mg prolonged-release tablets: yellow, capsule-shaped, biconvex, 6.6 mm x 11.9 mm, with "2392" printed on one side with black ink.
Doprilten 27 mg prolonged-release tablets: gray, capsule-shaped, biconvex, 6.7 mm x 12.0 mm, with "2393" printed on one side with black ink.
Doprilten 36 mg prolonged-release tablets: white, capsule-shaped, biconvex, 6.7 mm x 12.0 mm, with "2394" printed on one side with black ink.
Doprilten 54 mg prolonged-release tablets: brown-red, capsule-shaped, biconvex, 6.8 mm x 12.0 mm, with "2395" printed on one side with black ink.
Doprilten is available in high-density polyethylene (HDPE) bottles with a child-resistant polypropylene closure with an integrated silica gel desiccant.
Package sizes:
Contains 28, 30, and 90 prolonged-release tablets.
Only some package sizes may be marketed
Marketing Authorization Holder
Teva B.V.
Swensweg 5,
2031GA Haarlem,
Netherlands
Manufacturer
Balkanpharma – Dupnitsa AD
3 Samokovsko Shosse Str.
Dupnitsa 2600,
Bulgaria
Or
Merckle GmbH
Ludwig-Merckle-Strasse 3
Blaubeuren
89143
Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1ª planta
28108, Alcobendas, Madrid (Spain)
This medicine is authorized in the Member States of the European Economic Area under the following names:
Denmark Methylphenidate Actavis
Germany: Methylphenidat AbZ 18 mg Retardtabletten
Methylphenidat AbZ 27 mg Retardtabletten
Methylphenidat AbZ 36 mg Retardtabletten
Methylphenidat AbZ 54 mg Retardtabletten
Iceland Metylfenidat Actavis
Netherlands Methylfenidaat HCl retard Teva 18 mg, tabletten met verlengde afgifte
Methylfenidaat HCl retard Teva 27 mg, tabletten met verlengde afgifte
Methylfenidaat HCl retard Teva 36 mg, tabletten met verlengde afgifte
Methylfenidaat HCl retard Teva 54 mg, tabletten met verlengde afgifte
Norway Delmosart
Sweden Metylfenidat Actavis
Spain: Doprilten 18 mg prolonged-release tablets EFG
Doprilten 27 mg prolonged-release tablets EFG
Doprilten 36 mg prolonged-release tablets EFG
Doprilten 54 mg prolonged-release tablets EFG
Date of Last Revision of this Leaflet: December 2023
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es